3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate
© The Author(s) [2024]. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research..
Romosozumab treatment in women with postmenopausal osteoporosis increases bone formation while decreasing bone resorption, resulting in large BMD gains to reduce fracture risk within 1 year. DXA-based 3D modeling of the hip was used to assess estimated changes in cortical and trabecular bone parameters and map the distribution of 3D changes in bone parameters over time in patients from two randomized controlled clinical trials: FRAME (romosozumab vs placebo followed by denosumab) and ARCH (romosozumab vs alendronate followed by alendronate). For each study, data from a subset of ~200 women per treatment group who had total hip DXA scans at baseline and months 12 and 24 and had provided consent for future research were analyzed post hoc. 3D-SHAPER software v2.11 (3D-SHAPER Medical, Barcelona, Spain) was used to generate patient-specific 3D models from total hip DXA scans. Percentage changes from baseline to months 12 and 24 in areal BMD (aBMD), integral volumetric BMD (vBMD), cortical thickness, cortical vBMD, cortical surface BMD (sBMD), and trabecular vBMD were evaluated. Data from 377 women from FRAME (placebo, 190; romosozumab, 187) and 368 women from ARCH (alendronate, 185; romosozumab, 183) with evaluable 3D assessments at baseline and months 12 and 24 were analyzed. At month 12, treatment with romosozumab vs placebo in FRAME and romosozumab vs alendronate in ARCH resulted in greater increases in aBMD, integral vBMD, cortical thickness, cortical vBMD, cortical sBMD, and trabecular vBMD (P < 0.05 for all). At month 24, cumulative gains in all parameters were greater in the romosozumab-to-denosumab vs placebo-to-denosumab sequence and romosozumab-to-alendronate vs alendronate-to-alendronate sequence (P < 0.05 for all). 3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research - (2024) vom: 15. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lewiecki, E Michael [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cortical surface BMD |
|---|
| Anmerkungen: |
Date Revised 13.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/jbmr/zjae028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369675274 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369675274 | ||
| 003 | DE-627 | ||
| 005 | 20240313235933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jbmr/zjae028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1327.xml |
| 035 | |a (DE-627)NLM369675274 | ||
| 035 | |a (NLM)38477808 | ||
| 035 | |a (PII)zjae028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lewiecki, E Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) [2024]. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research. | ||
| 520 | |a Romosozumab treatment in women with postmenopausal osteoporosis increases bone formation while decreasing bone resorption, resulting in large BMD gains to reduce fracture risk within 1 year. DXA-based 3D modeling of the hip was used to assess estimated changes in cortical and trabecular bone parameters and map the distribution of 3D changes in bone parameters over time in patients from two randomized controlled clinical trials: FRAME (romosozumab vs placebo followed by denosumab) and ARCH (romosozumab vs alendronate followed by alendronate). For each study, data from a subset of ~200 women per treatment group who had total hip DXA scans at baseline and months 12 and 24 and had provided consent for future research were analyzed post hoc. 3D-SHAPER software v2.11 (3D-SHAPER Medical, Barcelona, Spain) was used to generate patient-specific 3D models from total hip DXA scans. Percentage changes from baseline to months 12 and 24 in areal BMD (aBMD), integral volumetric BMD (vBMD), cortical thickness, cortical vBMD, cortical surface BMD (sBMD), and trabecular vBMD were evaluated. Data from 377 women from FRAME (placebo, 190; romosozumab, 187) and 368 women from ARCH (alendronate, 185; romosozumab, 183) with evaluable 3D assessments at baseline and months 12 and 24 were analyzed. At month 12, treatment with romosozumab vs placebo in FRAME and romosozumab vs alendronate in ARCH resulted in greater increases in aBMD, integral vBMD, cortical thickness, cortical vBMD, cortical sBMD, and trabecular vBMD (P < 0.05 for all). At month 24, cumulative gains in all parameters were greater in the romosozumab-to-denosumab vs placebo-to-denosumab sequence and romosozumab-to-alendronate vs alendronate-to-alendronate sequence (P < 0.05 for all). 3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cortical surface BMD | |
| 650 | 4 | |a cortical thickness | |
| 650 | 4 | |a cortical volumetric BMD | |
| 650 | 4 | |a osteoporosis | |
| 650 | 4 | |a trabecular volumetric BMD | |
| 700 | 1 | |a Betah, Donald |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Libanati, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Oates, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yifei |e verfasserin |4 aut | |
| 700 | 1 | |a Winzenrieth, Renaud |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Serge |e verfasserin |4 aut | |
| 700 | 1 | |a Omura, Fumitoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research |d 1991 |g (2024) vom: 15. Feb. |w (DE-627)NLM012611115 |x 1523-4681 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jbmr/zjae028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 02 | ||